Japan
# |
Name |
Operating Income Margin |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
50.40%
|
Dec. 31, 2023 | USD 21.58 | 0.31% |
|
Japan |
|
2 |
46.88%
|
Dec. 31, 2023 | USD 9.76 | -1.43% |
|
Japan |
|
3 |
39.52%
|
Dec. 31, 2023 | USD 43.39 | 5.16% |
|
Japan |
|
4 |
39.41%
|
March 31, 2024 | USD 14.75 | -0.46% |
|
Japan |
|
5 |
32.45%
|
March 31, 2024 | USD 10.39 | -0.80% |
|
Japan |
|
6 |
29.43%
|
Aug. 31, 2024 | USD 9.32 | -2.24% |
|
Japan |
|
7 |
28.83%
|
Dec. 31, 2023 | USD 5.86 | -2.20% |
|
Japan |
|
8 |
28.74%
|
Sept. 30, 2024 | USD 2.93 | -1.24% |
|
Japan |
|
9 |
27.59%
|
Dec. 31, 2023 | USD 3.39 | -1.15% |
|
Japan |
|
10 |
27.43%
|
March 31, 2024 | USD 9.15 | -1.97% |
|
Japan |
|
11 |
27.08%
|
Oct. 31, 2023 | USD 5.47 | -1.74% |
|
Japan |
|
12 |
24.40%
|
Aug. 31, 2024 | USD 13.43 | 0.52% |
|
Japan |
|
13 |
23.73%
|
Dec. 31, 2023 | USD 3.77 | -0.24% |
|
Japan |
|
14 |
23.59%
|
Dec. 31, 2023 | USD 13.83 | -0.63% |
|
Japan |
|
15 |
21.67%
|
Dec. 31, 2023 | USD 14.95 | -1.71% |
|
Japan |
|
16 |
21.64%
|
March 31, 2024 | USD 25.58 | -1.99% |
|
Japan |
|
17 |
21.20%
|
March 31, 2024 | USD 9.19 | -0.31% |
|
Japan |
|
18 |
21.17%
|
March 31, 2024 | USD 24.26 | -0.77% |
|
Japan |
|
19 |
20.58%
|
June 30, 2024 | USD 16.87 | -2.21% |
|
Japan |
|
20 |
19.97%
|
Sept. 30, 2024 | USD 12.23 | -2.54% |
|
Japan |
|
21 |
19.52%
|
Dec. 31, 2023 | USD 9.78 | -1.94% |
|
Japan |
|
22 |
18.94%
|
March 31, 2024 | USD 4.97 | -1.23% |
|
Japan |
|
23 |
18.93%
|
Oct. 31, 2024 | USD 76.41 | -0.92% |
|
Japan |
|
24 |
18.89%
|
March 31, 2024 | USD 43.36 | -1.17% |
|
Japan |
|
25 |
18.04%
|
March 31, 2024 | USD 8.69 | -1.39% |
|
Japan |
|
26 |
17.89%
|
March 31, 2024 | USD 11.36 | -0.42% |
|
Japan |
|
27 |
17.57%
|
March 31, 2024 | USD 3.56 | -3.55% |
|
Japan |
|
28 |
16.98%
|
March 31, 2024 | USD 19.21 | -1.38% |
|
Japan |
|
29 |
15.74%
|
March 31, 2024 | USD 10.95 | -0.53% |
|
Japan |
|
30 |
15.32%
|
March 31, 2024 | USD 10.75 | -2.71% |
|
Japan |
|
31 |
15.20%
|
March 31, 2024 | USD 18.88 | -4.20% |
|
Japan |
|
32 |
14.21%
|
March 31, 2024 | USD 29.12 | 0.44% |
|
Japan |
|
33 |
13.42%
|
March 31, 2024 | USD 13.76 | -1.19% |
|
Japan |
|
34 |
13.27%
|
March 31, 2024 | USD 29.51 | -0.48% |
|
Japan |
|
35 |
13.21%
|
March 31, 2024 | USD 27.56 | -3.63% |
|
Japan |
|
36 |
13.20%
|
March 31, 2024 | USD 27.19 | -2.00% |
|
Japan |
|
37 |
13.00%
|
Dec. 31, 2023 | USD 8.94 | -0.23% |
|
Japan |
|
38 |
12.84%
|
March 31, 2024 | USD 12.31 | 0.15% |
|
Japan |
|
39 |
12.83%
|
March 31, 2024 | USD 14.41 | -0.72% |
|
Japan |
|
40 |
11.26%
|
June 30, 2024 | USD 8.27 | -1.43% |
|
Japan |
|
41 |
11.09%
|
March 31, 2024 | USD 11.15 | -1.27% |
|
Japan |
|
42 |
10.68%
|
March 31, 2024 | USD 12.96 | -0.41% |
|
Japan |
|
43 |
10.66%
|
March 31, 2024 | USD 31.28 | -0.59% |
|
Japan |
|
44 |
10.37%
|
March 31, 2024 | USD 3.38 | -1.89% |
|
Japan |
|
45 |
9.29%
|
Feb. 29, 2024 | USD 28.70 | -1.67% |
|
Japan |
|
46 |
8.85%
|
Dec. 31, 2023 | USD 4.79 | -1.78% |
|
Japan |
|
47 |
8.83%
|
March 31, 2024 | USD 14.30 | -1.12% |
|
Japan |
|
48 |
8.64%
|
Sept. 30, 2024 | USD 3.00 | -0.80% |
|
Japan |
|
49 |
8.59%
|
March 31, 2024 | USD 17.48 | -1.21% |
|
Japan |
|
50 |
8.43%
|
March 31, 2024 | USD 13.78 | -1.19% |
|
Japan |
The Healthcare company in Japan with the highest Operating Income Margin is GNI Group Ltd. (Tokyo Stock Exchange: 2160.T) at 50.40%.
The Healthcare company in Japan with the lowest Operating Income Margin is BrightPath Biotherapeutics Co., Ltd. (Tokyo Stock Exchange: 4594.T) at -1,604,276.39%.
The top 10 Healthcare companies in Japan by Operating Income Margin are GNI Group Ltd., Mizuho Medy Co.,Ltd., Chugai Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Ono Pharmaceutical Co., Ltd., Mani, Inc., FINDEX Inc., Kanamic Network Co.,LTD, Medical Data Vision Co., Ltd. and M3, Inc..
The bottom 10 Healthcare companies in Japan by Operating Income Margin are BrightPath Biotherapeutics Co., Ltd., Oncolys BioPharma Inc., NanoCarrier Co., Ltd., Solasia Pharma K.K., OncoTherapy Science, Inc., MEDINET Co., Ltd., Welby Inc., Nxera Pharma Co., Ltd., Carna Biosciences, Inc. and Precision System Science Co., Ltd..